Circulating antibodies to α-enolase and phospholipase A₂ receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy

Yukihiro Kimura¹ · Naoto Miura¹ · Hanna Debiec² · Hiroyuki Morita¹ · Harutaka Yamada³ · Shogo Banno¹ · Pierre Ronco² · Hirokazu Imai¹

Received: 3 June 2015 / Accepted: 16 January 2016 / Published online: 1 February 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Background Phospholipase A₂ receptor (PLA₂R) is recognized as a target antigen in primary membranous nephropathy (MN); Anti-α-enolase antibody in primary and secondary MN has been proposed, however, little is known about the potential contribution of α-enolase to the pathogenesis of MN.

Methods We evaluated circulating antibodies to α-enolase by a dot blotting system and PLA₂R by indirect immunofluorescence, and glomerular deposition of these proteins in 25 patients with primary MN, 20 patients with secondary MN, 44 patients with collagen disease or septic infection, 60 patients with nephritis (each ten patients of IgA nephropathy, focal segmental gloemrulosclerosis, minimal change nephrotic syndrome, membranoproliferative glomeurlonephritis, diabetic glomerulosclerosis, and tubulointerstitial nephritis) as disease control, and 20 healthy subjects.

Results In primary MN, 18 of 25 sera (72 %) showed anti-α-enolase antibody (IgG1 and IgG4, 11 pts; IgG4 alone, six pts; IgG1 alone, one pt). In secondary MN, 15 of 20 sera (75 %) contained anti-α-enolase antibody (IgG1 and IgG3, 13 pts; IgG3 alone, two pts). No circulating anti-α-enolase antibody was found in 44 collagen diseases or septic patients, 60 nephritis without MN, and 20 healthy subjects. Twelve of 25 sera (48 %) from patients with primary MN were positive for anti-PLA₂R antibody, whereas all patients with secondary MN were negative. Eight of the 12 PLA₂R-positive patients (67 %) with primary MN also had anti-α-enolase antibody. Although PLA₂R antigen was present in a subepithelial pattern in 10 of 19 (52 %) patients with primary MN, α-enolase was never detected in glomerular deposits in 19 and ten patients with primary and secondary MN, respectively.

Conclusions Circulating anti-α-enolase antibodies are highly present in both primary and secondary MN (about 70 %, respectively), while anti-PLA₂R antibodies are specific for primary MN (48 %) with a prevalence apparently lower in the Japanese population than in Chinese and Caucasian populations. The absence of α-enolase from subepithelial immune deposits suggests that anti-α-enolase antibodies do not contribute directly to immune-deposit formation, although they may have other pathogenic effects.

Keywords α-Enolase · Phospholipase A₂ receptor · Membranous nephropathy

Introduction

Membranous nephropathy (MN)—a major glomerular disease and common cause of adult nephrotic syndrome—is characterized by glomerular subepithelial IgG deposits [1]. Primary MN is predominantly associated with
glomerular deposition of the IgG4 subtype although variable amounts of IgG1 were also detected in immune deposits [2–6], whereas secondary MN is characterized by prevailing deposits of IgG1, IgG2, and IgG3 [6–8]. During the past decade, several breakthroughs have occurred with the identification of several candidate human antigens in MN. In infants with MN, Debiec et al. detected anti-neutral endopeptidase antibodies that were produced by mothers who lacked this enzyme [9, 10]. Beck et al. demonstrated that IgG4 antibodies specific for M-type phospholipase A2 receptor (PLA2-R) were present in glomerular eluates and serum from adult patients with primary MN [11]. Other candidate autoantigens in patients with primary MN include superoxide dismutase 2 (SOD2), aldose reductase [12] and α-enolase [13–15]. Debiec et al. reported that some patients who develop MN in early childhood had circulating anti-bovine serum albumin (BSA) antibodies and cationic BSA as a component of glomerular immune deposits [16]. Recently, Anti-thrombospondine type-1 domain-containing 7A antibody was reported in 10 % of primary MN patients [17]. Interestingly, unlike other antibodies identified in patients with autoimmune MN, anti-α-enolase antibodies have been found in both primary and secondary MN [13, 14, 18]. In the present study, we examined the potential relationship between circulating anti-α-enolase antibodies and anti-PLA2-R antibodies, and the glomerular deposition of α-enolase and PLA2-R proteins in Japanese patients with primary and secondary MN.

Materials and methods

This study was approved by the Ethics Committee at Aichi Medical University (10–127).

Patients’ characteristics

We included Japanese patients with MN who were admitted to Aichi Medical University Hospital and affiliated hospitals between 2003 and 2011. Diagnosis of MN was based on light microscopy, immunofluorescence, and electron microscopy analyses of kidney biopsy specimens [19]. Primary MN was defined according to morphologic criteria after excluding known underlying diseases and drug exposure. Sera from 25 patients with primary MN, 20 patients with secondary MN, 44 patients with collagen diseases or severe infection, 60 patients with nephritis without MN (each ten patients of IgA nephropathy, focal segmental glomerulosclerosis, minimal change nephrotic syndrome, membranoproliferative glomerulonephritis, diabetic glomerulosclerosis, and tubulointerstitial nephritis) as disease control, and 20 healthy subjects were stored at −80 °C until use. Sera from all patients with MN were obtained before steroid and immunosuppressive treatment with the approval of the institutional ethics committee. Patients’ characteristics are summarized in Tables 1 and 2. Complete remission was defined as urinary protein excretion of less than 300 mg/day as a result of therapeutic intervention such as prednisolone with or without immunosuppressive drugs; spontaneous remission was defined as complete remission in a patient receiving anti-platelets or anti-hypertensive drugs only. Partial remission was defined as proteinuria <3.5 g/day with a decrease of proteinuria <50 % from baseline and stable renal function.

Preparation of α-enolase deletion mutants

We obtained sequence encoding full-length human α-enolase (433 amino acids; GenBank AK315417, Ensemble: ENSG00000074800). As a result of post-translational modification, human α-enolase is a 47-kDa glycoprotein. Complementary DNA (cDNA) cloning and production of fusion proteins were described elsewhere [20]. Briefly, full-length and truncated cDNA encoding human α-enolase was amplified in polymerase chain reactions, and ligated to sequence encoding glutamine S-transferase (GST) (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). DNA was cloned into pGEX plasmids and transformed into JM109 cells (Promega, USA), and protein expression was induced using isopropyl-β-D-thiogalactopyranoside. After protein extraction from JM109 cells, tagged proteins were affinity purified using glutathione-Sepharose 4B (Amersham Pharmacia Biotech).

Anti-α-enolase antibody by western and dot blot analysis

Nitrocellulose membranes (GE Healthcare, UK) were washed in PBS (Wako Pure Chemical Industries, Japan) containing 10 ng/ml recombinant α-enolase protein and 5 % (w/v) skim milk (BD Difco, USA) for 60 min at room temperature in non-reducing conditions. The membrane was washed three times with PBS containing 0.05 % Tween (Katayama Chemical Industries, Japan), and incubated with patient serum at a dilution of 1:200. After three washes in PBS containing 0.05 % Tween, the membrane was incubated with horseradish peroxidase–conjugated anti-human IgG antibodies at a dilution of 1:1000 (Sigma-Aldrich, USA), and peroxidase–conjugated mouse monoclonal antibodies to human IgG1, IgG2, IgG3, IgG4 at a dilution of 1:500 (Invitrogen, USA). After three washes, reaction product on the membrane was visualized using an

 Springer
enhanced chemiluminescence system (ChemiLumit Kit, GE Health Care, UK). Photographic images were obtained using an LAS-1000 system (FujiFilm Co., Japan). Image Reader Lite for LAS-1000 plus Ver. 1.3 (FujiFilm Co.) was used to capture the images, which were edited using Adobe Photoshop, when necessary.

Anti-PLA2R antibody by indirect immunofluorescence

Anti-PLA2R specific autoantibody titers were measured as previously described based on indirect immunofluorescence in HEK 293 cells that were transiently transfected with full-length cDNA encoding PLA2R (Euroimmun) [21]. Antibody positivity was defined as positive staining at serum dilutions of at least 1/10. Negative results for anti-PLA2R antibodies were defined as an absence of detectable signals at an antibody dilution of 1/10.

Table 1 Characteristics of patients with primary membranous nephropathy

| Age | Sex | Stage of MN | Amount of urinary protein (g/day) | Serum albumin (g/dl) | Serum creatinine (mg/dl) | Anti-α-enolase antibody | PLA2R AB | IgG subclass | PLA2R in biopsy | Treatment |
|-----|-----|-------------|----------------------------------|----------------------|-------------------------|-------------------------|----------|-------------|----------------|-----------|
| MN-1 | 52  | F           | I                                | 2.60                 | 3.0                     | 0.52                    | Pos 1 + 4 | Pos 4       | Pos            | PSL + MZR |
| MN-2 | 74  | M           | I to II                          | 4.05                 | 1.6                     | 0.75                    | Pos 4    | Pos 1 + 4   | Pos            | PSL + MZR |
| MN-3 | 18  | M           | I                                | 1.41                 | 3.5                     | 0.38                    | Pos 1 + 4 | Neg         | Neg            | Na        |
| MN-4 | 77  | M           | I                                | 3.04                 | 1.4                     | 1.00                    | Neg      | Neg         | Pos 4          | Na        |
| MN-5 | 43  | M           | I to II                          | 6.86                 | 2.8                     | 0.69                    | Pos 1 + 4 | Neg         | Neg            | Na        |
| MN-6 | 65  | M           | III                              | 0.58                 | 4.1                     | 0.85                    | Pos 1    | Neg         | Neg            | Na        |
| MN-7 | 70  | M           | II to III                        | 4.46                 | 2.4                     | 0.85                    | Pos 1 + 4 | Pos 4       |                | Na        |
| MN-8 | 75  | F           | II                               | 3.00                 | 2.4                     | 1.05                    | Pos 1 + 4 | Pos 1 + 4   | Na            | Unknown  |
| MN-9 | 62  | F           | I to II                          | 0.62                 | 2.9                     | 0.48                    | Pos 1 + 4 | Neg         | Neg            | Pos       |
| MN-10 | 65   | M           | I                                | 4.16                 | 2.4                     | 0.88                    | Neg      | Neg         | Pos 4          | Pos       |
| MN-11 | 62   | M           | II                               | 3.40                 | 2.7                     | 0.79                    | Pos 4    | Pos 4       | Pos            | Pos       |
| MN-12 | 52   | F           | I                                | 5.00                 | 1.9                     | 0.59                    | Neg      | Neg         | Neg            | Na        |
| MN-13 | 77   | F           | I                                | 3.15                 | 1.3                     | 0.57                    | Neg      | Neg         | Neg            | Na        |
| MN-14 | 61   | F           | I                                | 8.00                 | 1.6                     | 0.45                    | Neg      | Neg         | Pos 4          | Unknown  |
| MN-15 | 69   | M           | I to II                          | 4.44                 | 2.9                     | 1.54                    | Pos 1 + 4 | Neg         | Neg            | Pos       |
| MN-16 | 58   | F           | I to II                          | 1.10                 | 3.8                     | 0.44                    | Pos 4    | Pos 4       | Pos            | PSL + MZR |
| MN-17 | 33   | M           | I                                | 1.16                 | 3.2                     | 0.72                    | Neg      | Neg         | Neg            | Na        |
| MN-18 | 47   | F           | I to II                          | 2.62                 | 2.7                     | 0.77                    | Pos 1 + 4 | Neg         | Neg            | Na        |
| MN-19 | 69   | F           | I                                | 8.47                 | 2.1                     | 0.98                    | Pos 1 + 4 | Neg         | Neg            | Na        |
| MN-20 | 57   | F           | I                                | 1.24                 | 1.8                     | 0.97                    | Neg      | Neg         | Pos 1 + 4      | Pos       |
| MN-21 | 73   | M           | I to II                          | 6.41                 | 3.0                     | 1.04                    | Pos 4    | Pos 4       | Pos            | ARB       |
| MN-22 | 56   | M           | II to III                        | 0.30                 | 3.4                     | 0.68                    | Pos 1 + 4 | Neg         | Neg            | Unknown  |
| MN-23 | 65   | M           | I                                | 0.42                 | 3.6                     | 0.77                    | Pos 1 + 4 | Neg         | Neg            | None      |
| MN-24 | 68   | M           | II                               | 0.67                 | 3.3                     | 0.67                    | Pos 4    | Neg         | Neg            | ARB       |
| MN-25 | 77   | M           | I                                | 1.82                 | 2.8                     | 0.92                    | Pos 4    | Pos 4       | Pos            | ARB       |

ARB angiotensin II receptor blocker, MN membranous nephropathy, MZR mizoribin, na not available, PSL prednisolone, PLA2R AB anti-PLA2R antibody

Glomerular deposition of α-enolase and PLA2R proteins

α-Enolase and PLA2R were detected in paraffin-embedded native biopsies under a confocal microscope using affinity-purified specific anti-rabbit α-enolase (AbD serotec) and PLA2R antibodies (Atlas Antibodies, Stockholm, Sweden) followed by goat Alexa 488 conjugated anti-rabbit IgG Fab fragments (Molecular Probes, Eugene, OR, USA) as previously described [21]. Staining with only secondary antibodies produced negative results for all biopsies.

Statistical analysis

Data were analyzed using Microsoft Excel software. Normally distributed variables were described as mean standard deviation and compared across primary and secondary MN using analysis of variance. Age, amount of urinary protein

Clin Exp Nephrol (2017) 21:117–126
protein, and serum creatinine were compared using Student’s t test. Mann–Whitney U tests (nonparametric) were used to compare results for anti-α-enolase antibody positivity in patients with MN and control subjects. All p values are two tailed, with <0.05 considered statistically significant.

Results

Patients’ characteristics

The study comprised 25 patients with primary MN, and 20 patients with secondary MN (seven patients had bucillamine-induced nephropathy and 13 patients had lupus nephritis World Health Organization type V). Patients’ characteristics are summarized in Tables 1 and 2. The mean age of the patients with primary and secondary MN was 61.0 ± 14.4 and 48.7 ± 16.3 years, respectively (p < 0.01). The mean serum creatinine level was 0.77 ± 0.25 and 0.67 ± 0.18 mg/dl (p = 0.07), and mean proteinuria was 3.16 ± 2.39 g/day and 3.47 ± 3.13 mg/day (p = 0.6), at the time of diagnosis in primary and secondary MN, respectively. Treatment modalities were not known in seven patients. One patient received dipyridamole alone, 29 patients were treated with prednisolone with or without other immunosuppressants including Mizoribine (an immunosuppressive agent used in Japan), six patients were treated with angiotensin II receptor blocker (ARB) alone, and two patients received no therapy.

Detection of anti-α-enolase antibody

We first examined whether sera from patients with MN contained antibodies specific for recombinant α-enolase. Sera from 18 of 25 patients with primary MN (72 %) were immunoreactive with α-enolase. Nine of 13 patients with lupus nephritis (World Health Organization class V), (69 %) and six of seven patients with bucillamine-induced MN (86 %) were positive for anti-α-enolase antibodies (Fig. 1a). The inhibition tests showed highly specific antibody to α-enolase (supplementary materials I). In contrast, sera from 44 collagen diseases or septic patients, 60 nephritis without MN as disease controls (Fig. 1b), and 20 healthy controls did not react with α-enolase.
IgG subclasses of circulating anti-α-enolase antibodies

We then characterized IgG subclasses of anti-α-enolase antibodies in both primary and secondary MN (Fig. 2). In primary MN, most antibodies appeared to be IgG1 or IgG4; 72% of patients being positive for at least one of these subclasses on dot blots. In secondary MN, however, IgG1 and IgG3 produced the strongest signals, with positive results observed in 75% of patients, contrasting very little or absent IgG4 reactivity. Serum from each patient that immunoreacted with full-length α-enolase also was positive with the N- and C-terminal fragments (amino-acid stretch 1–66 and 349–433, respectively) (supplementary materials 2-5). Further to test whether the N- and C-termini have closely related epitopes, we blocked reactivity to the N-terminal fragment with the C-terminal fragment and conversely. The results suggest that the epitope/s at the both ends of protein are partially related. However, further studies are necessary to identify an exact epitope (or epitopes) recognized by circulating antibodies.

Circulating anti-α-enolase antibodies before and after treatment

We examined the effects of treatment on circulating antibodies specific for α-enolase in a patient with primary MN, a lupus nephritis patient with lupus MN, and three patients with bucillamine-induced MN, who all attained complete remission after treatment. We also assessed three patients with primary MN and one patient with lupus MN who failed to achieve complete remission despite therapy. Notably, circulating antibodies were no longer detected in each of the patients who reached complete remission (Fig. 3). Among the 4 patients who failed to attain complete remission, antibody titers were markedly decreased in the patient with lupus MN, and in two of three patients with primary MN, and unchanged in the remaining patient with prevailing IgG1 (Fig. 3).

Anti-PLA2R antibody

Twelve of 25 (48%) tested sera from patients with primary MN had anti-PLA2R antibodies (Table 1). Of the 12 PLA2R-positive patients, 8 were positive for anti-α-enolase, 4 were negative. Of the 13 PLA2R-negative patients, 10 were positive for anti-enolase. None of the 19 examined patients with secondary MN were positive for anti-PLA2R antibodies (Table 2).

Glomerular deposition of PLA2R and α-enolase proteins

In paraffin-embedded kidney biopsy specimens, confocal microscopy showed the presence of PLA2R in subepithelial
deposits along glomerular capillary loops (Figs. 4a, 5a) in 10 of 19 patients with primary MN. Nine of the ten patients also had circulating anti-PLA2R antibodies (Table 1). PLA2R was absent in the 10 examined biopsy specimens from patients with lupus- and bucillamine-related MN (Fig. 4b, c).

α-enolase was strongly expressed in tubular epithelium and was weak positive in glomerular parietal cells (Fig. 4d, e, f) and very weakly detected in the cytoplasm of glomerular cells on high magnification (Fig. 5b), but unlike PLA2R, α-enolase was never detected in subepithelial deposits in the 29 biopsy specimens where this was examined (Fig. 5b). The pattern of expression for α-enolase was the same in all groups, irrespective of the presence or absence of circulating anti α-enolase antibodies. Human IgG-adsorbed primary and secondary antibodies tested on frozen sections gave no signal in glomeruli but still well visible staining in proximal tubules (supplementary materials 6).

Discussion

Our study provides important data on immunopathology of MN. It first shows that circulating anti-α-enolase IgG4 antibodies, with or without IgG1 antibodies, were present in 72% of the patients with primary MN, while anti-α-enolase IgG3 antibodies, with or without IgG1 antibodies, were detected in 75% of those with secondary MN. Circulating antibodies disappeared in the few tested patients undergoing complete remission. Second, we showed a low prevalence (48%) of anti-PLA2R antibodies in this small cohort of Japanese patients with primary MN assessed before treatment, with eight of 25 patients producing both antibodies (32%), while we could not detect anti-PLA2R antibodies in secondary MN such as bucillamine-induced MN where they had not been searched as yet. Third, we could not detect α-enolase in subepithelial immune deposits in any of the patient with circulating anti-α-enolase antibodies, which questions their role in the pathogenesis of MN, including PLA2R-unrelated MN, whereas PLA2R was detected in the deposits in all nine tested patients with anti-PLA2R antibodies and in one patient without circulating antibodies.

Anti-α-enolase antibodies have been reported in patients with a large variety of autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and autoimmune mediated retinopathy (AR) [22], with a prevalence of 21, 25%, and about 30%, respectively [23–25]. Based on our results and those from Wakui et al. approximately 70% patients with
primary or secondary MN carry anti-α-enolase antibodies [13]. We detected mostly IgG4 and IgG1 anti-α-enolase antibodies in primary MN, and IgG3 and IgG1 anti-α-enolase antibodies in secondary MN, while Wakui et al. predominantly identified IgG1 and IgG3 anti-α-enolase antibodies. These discrepancies might be due to different affinities of the anti-subclass antibodies used for detection. More recently, Bruschi et al. found that anti-α-enolase IgG4 antibody levels were high in only 25% of patients with primary MN [14]. The different prevalence of anti-α-enolase antibodies between Japanese and Italian populations may reflect underlying genetic factors, including human leukocyte antigen polymorphisms. Although anti-α-enolase antibodies were reported to be detected in sera of healthy subjects [26, 27], we could not detect anti-α-enolase antibodies in disease controls including those with connective disease like Bruschi et al. [14]. One possible explanation of this discrepancy might be the technical approaches and their different sensitivity and specificity.

Because of the apparently wide spectrum of diseases associated with anti-α-enolase antibodies, these antibodies by themselves cannot help for the diagnosis of specific autoimmune diseases. Therefore determination of immunoreactive sequences of α-enolase associated with disease-specific pathogenic autoantibodies is of great importance. Epitope mapping performed in cancer-associated retinopathy (CAR) showed the epitope located between amino-acids 56 and 63 (56–63aa) being specifically associated with pathogenic sera [28]. In endometriosis, anti-α-enolase antibodies bound to two epitopes at 53–87aa and 207–238aa and shared reactivity against the epitope 56–63aa with CAR patients [29]. The epitope for pathogenic antibodies in Hashimoto’s encephalopathy is located in the N-terminal part of α-enolase protein [30]. In our patients, antibodies bound to epitopes located in the first 66aa at the N-terminal end and in the last 84aa at the C-terminal end of the protein. The next step will be to perform fine epitope mapping of these regions, and to investigate the pathogenic relevance of these epitopes.

α-Enolase is an ubiquitous cytoplasmic glycolytic enzyme involved in the synthesis of pyruvate [31]. In addition to its glycolytic function, this 47-kDa glycoprotein exerts many other functions related to its subcellular location [31]. Different cellular localizations of potential MN auto-antigens are seen under normal physiologic conditions. While neutral endopeptidase and PLA2R are expressed on cell surface of podocytes [9, 11, 32], aldose reductase and SOD2 are cytoplasmic/mitochondrial enzymes which can be enhanced at the cell surface after oxidative stress [12]. Similarly, α-enolase is usually cytoplasmic but its expression varies according to the cell conditions and can be expressed at the surface of many eukaryotic cells [31].

Although circulating anti-α-enolase antibodies were commonly found, unlike PLA2R, α-enolase was never detected in subepithelial immune deposits, in contrast with the observations made by Bruschi et al. [14]. We used human IgG-adsorbed primary and secondary antibodies tested on frozen sections gave no signal of α-enolase in glomeruli but still well visible staining in proximal tubules. This finding suggests that anti-α-enolase antibody does not directly contribute to the formation of subepithelial immune deposits and resulting complement activation. We cannot, however, exclude a pathogenic role for anti-α-enolase antibodies through binding to endothelial or podocyte cell surface, and subsequent alteration of cell functions. Alterations induced by binding of anti-α-enolase
antibodies to the surface of endothelial cells or podocytes may increase permeability of the capillary wall, leading to enhanced access and accumulation of pathogenic antibodies such as anti-PLA2R. Furthermore, because α-enolase has pleiotropic effects, antibodies may perturb other important cellular functions. For instance, anti-α-enolase antibodies were shown to inhibit the binding of plasminogen to α-enolase on cell surface, which means protective effects from proteolytic activities of plasmin [33, 34]. On the contrary, intracellular anti-α-enolase antibodies taken-up by endocytosis may interfere with glycolysis, decrease cellular ATP levels, and increase intracellular Ca$^{2+}$, which ultimately may induce apoptosis [35].

We found that the prevalence of anti-PLA2R antibodies in previously untreated patients (48 %) was lower than that

![Fig. 4](image1)

**Fig. 4** Glomerular deposition of PLA2R and α-enolase proteins in primary and secondary MN analyzed by confocal microscopy. PLA2R was present in primary MN (a), but not in secondary MN due to lupus nephritis (LN) and bucillamine (BUC) (b, c). α-enolase was strongly expressed in tubular epithelium and was weak positive in glomerular parietal cells (d, e, f), but was not detected in subepithelial deposits along glomerular capillary loops as was shown for PLA2R in primary MN.

![Fig. 5](image2)

**Fig. 5** High magnification of PLA2R and α-enolase proteins in primary MN. PLA2R was detected in subepithelial deposits along glomerular capillary loops (a) whereas α-enolase was never detected in subepithelial deposits (b).
previously reported in Caucasian, African, and Chinese cohorts [11, 36–38], suggesting an effect of the genetic background. Akiyama et al. reported similar data that 53 % of patients with idiopathic MN in Japan [39].

In conclusion, circulating anti-\( \alpha \)-enolase antibody was detected in about 70 % of patients with both primary and secondary MN, while anti-PLA\(_2\)R antibody was restricted to primary MN. The absence of glomerular deposition of \( \alpha \)-enolase in subepithelial area contrasting with the presence of PLA\(_2\)R in immune deposits, suggests that instead of being implicated in the formation of immune deposits, anti-\( \alpha \)-enolase antibody binding to glomerular cell surface might increase access to the podocyte of other antibodies such as anti-PLA2R, and thus be an enhancing event in primary and secondary MN. Further studies on larger cohorts are needed to confirm this hypothesis and to delineate the value of anti-\( \alpha \)-enolase antibody as biomarker for diagnosis and monitoring of MN patients and of \( \alpha \)-enolase as potential therapeutic target.

Acknowledgments YK was partially supported by a grant from the Aichi Medical University Alumni Association, PR and HD were supported by grant from Agence Nationale de la Recherche (ANR-07-Physio-016-01), and a grant from the European Community of the 7th Framework Program (Grant Agreement Number HEALTH-F2-2007-201590).

Compliance with ethical standards

Conflict of interest None declared.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. 2010;56(1):157–67.
2. Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58(1):57–62.
3. Kuroki A, Shibata T, Honda H, et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002;41(11):936–42.
4. Segawa Y, Hisano S, Matsushita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol. 2010;25(6):1091–9.
5. Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis. 1994;23(3):358–64.
6. Imai H, Hamai K, Komatsuda A, et al. IgG subclasses in patient with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51(1):270–6.
7. Nagahama K, Matsushita H, Hara M, et al. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39(4):706–12.
8. Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. N Engl J Med. 2002;346(26):2053–60.
9. Debiec H, Guigonis V, Mougenot B, et al. Antenal membranous glomerulonephritis from to anti-neutral endopeptidase antibodies. N Engl J Med. 2004;19(3):574–9.
10. Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenal glomerulopathies. Lancet. 2004;364(9441):1252–9.
11. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.
12. Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010;21(3):507–19.
13. Wakui H, Imai H, Komatsuda A, et al. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy. Clin Exp Immunol. 1999;118(3):445–50.
14. Bruschi M, Carnevali ML, Murtas C, et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics. 2011;74(10):2008–17.
15. Murtas C, Bruschi M, Candiano G, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(9):1394–400.
16. Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011;364(22):2101–10.
17. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-I domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–87.
18. Migliorini P, Pratesi F, Bongiorni F, et al. The targets of nphritogenic antibodies in systemic autoimmune disorders. Autoimmun Rev. 2002;1(3):168–73.
19. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney, edn 6, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–51.
20. Yamada H, Misra N, Kitagawa W, et al. Membranous nephropathy and pulmonary alveolar proteinosis. Intern Med. 2007;46(7):1441–6.
21. Debiec H, Ronco P, PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689–90.
22. Terrier B, Degand N, Guilpain P, et al. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev. 2007;6(3):176–82.
23. Moscato S, Pratesi F, Sabbatini A, et al. Autoimmunity in connective tissue disorders. Eur J Immunol. 2001;31(10):2373–80.
24. Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase, recognized by autoantibodies in infectious and autoimmune diseases. Autoimmun Rev. 2002;1(3):168–73.
25. Moscato S, Pratesi F, Bongiorni F, et al. The targets of nphritogenic antibodies in systemic autoimmune disorders. Autoimmun Rev. 2002;1(3):168–73.
26. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney, edn 6, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–51.
27. Yamada H, Misra N, Kitagawa W, et al. Membranous nephropathy and pulmonary alveolar proteinosis. Intern Med. 2007;46(7):1441–6.
28. Debiec H, Ronco P, PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689–90.
29. Terrier B, Degand N, Guilpain P, et al. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev. 2007;6(3):176–82.
30. Moscato S, Pratesi F, Sabbatini A, et al. Surface expression of a glycolytic enzyme, alpha-enolase, recognized by autoantibodies in connective tissue disorders. Eur J Immunol. 2000;30(12):3575–84.
31. Saulot V, Vittecoq O, Charlionet R, et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum. 2002;46(5):1156–201.
32. Moscato M, Chimenti D, Pratesi F, et al. Prevalence and clinicoserological correlations of anti-alpha-enolase, anti-C1q, and antidualDNA antibodies in patients with systemic lupus erythematosus. J Rheumatol. 2006;33(4):695–7.
33. Adamus G, Aptsiauri N, Guy J, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol. 1996;78(2):120–9.
27. Servetaz A, Guipil P, Camoin L, et al. Identification of target antigens of antiendothelial cell antibodies in healthy individuals: a proteomic approach. Proteomics. 2008;8:1000–8.
28. Adamus G, Amundson D, Seigel GM, et al. Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells. J Autoimmun. 1998;11(6):671–7.
29. Walter M, Berg H, Leidenberger FA, et al. Autoreactive epitopes within the human alpha-enolase and their recognition by sera from patients with endometriosis. J Autoimmun. 1995;8(6):931–45.
30. Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy. J Neuroimmunol. 2005;162(1–2):130–6.
31. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci. 2001;58(7):902–20.
32. Ronco P, Debiec H. Advances in membranous nephropathy: success stories of a long journey. Clin Exp Pharmacol Physiol. 2011;38(7):410–6.
33. Lopez-Alemany R, Suelves M, Diaz-Ramos A, et al. Alpha-enolase plasminogen receptor in myogenesis. Front Biosci. 2005;10(1):30–6.
34. Capello M, Ferri-Borgonno S, Cappello P, et al. α-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J. 2011;278(7):1064–74.
35. Magrys A, Anekonda T, Ren G, et al. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol. 2007;27(2):181–92.
36. Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137–43.
37. Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol. 2012;8(4):203–13.
38. Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012; doi:10.1038/ki.2012.209.
39. Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2014 Nov 21. [Epub ahead of print].